Literature DB >> 8024782

Phagemid pSIT permits efficient in vitro mutagenesis and tightly controlled expression in E. coli.

M Andreansky1, E Hunter.   

Abstract

A new phagemid vector, pSIT, was constructed that allows both oligonucleotide-directed mutagenesis and tightly controlled, high-level expression of proteins in Escherichia coli. An efficient rate of mutagenesis is achieved by taking advantage of the double oligonucleotide primer technique. In addition to the mutagenic primer, a second oligonucleotide primer conferring antibiotic resistance to the mutant DNA strand is annealed to single-strand DNA. Selection for the antibiotic thus increases the frequency of mutants. High-level and tightly controlled expression of heterologous proteins is enabled by utilizing a very strong hybrid T7lac promoter and lac repressor in conjunction with T7 RNA polymerase, as well as a high copy number of the vector. The pSIT phagemid permits overexpression of proteins and their mutants without subclonings from mutagenic to expression constructs, which saves time, especially when multiple mutations of the same protein are proposed. A retroviral proteinase precursor, toxic for E. coli, was successfully expressed to a high level, and a series of mutants of this protein was readily obtained.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024782

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  3 in total

1.  Analysis of Mason-Pfizer monkey virus Gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape.

Authors:  M Rumlova-Klikova; E Hunter; M V Nermut; I Pichova; T Ruml
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus.

Authors:  M Sakalian; E Hunter
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  The impact of altered polyprotein ratios on the assembly and infectivity of Mason-Pfizer monkey virus.

Authors:  Zdena Kohoutová; Michaela Rumlová; Martin Andreánsky; Michael Sakalian; Eric Hunter; Iva Pichová; Tomás Ruml
Journal:  Virology       Date:  2008-12-04       Impact factor: 3.616

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.